{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:DOC-X1P22C2O/9661c242-979f-42ac-ae92-329e1192d0ac/PDF","dcterms:extent":"2965 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:DOC-X1P22C2O/4bbf678e-ca90-42f1-80a5-e4bccdbccec3/TEXT","dcterms:extent":"17 KB"}],"edm:TimeSpan":{"@rdf:about":"1992-2025","edm:begin":{"@xml:lang":"en","#text":"1992"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:DOC-X1P22C2O","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:SPR-WQVGMCSC"},{"@xml:lang":"sl","#text":"Acta dermatovenerologica Alpina, Pannonica et Adriatica"}],"dcterms:issued":"1993","dc:creator":["Biro, J...","Cserhalmi, J... P.","Horvath, A...","Jakob, E...","Marschalko, M...","Papp, I..."],"dc:format":[{"@xml:lang":"sl","#text":"letnik:2"},{"@xml:lang":"sl","#text":"številka:3"},{"@xml:lang":"sl","#text":"str. 87-90"}],"dc:identifier":["ISSN:1318-4458","COBISSID_HOST:2639321","URN:URN:NBN:SI:doc-X1P22C2O"],"dc:language":"en","dc:publisher":{"@xml:lang":"sl","#text":"Slovene Welding Society"},"dc:subject":[{"@xml:lang":"sl","#text":"Adrenal cortex hormones"},{"@xml:lang":"sl","#text":"Adverse effects"},{"@xml:lang":"sl","#text":"Cyclosporins"},{"@xml:lang":"sl","#text":"Dermatomyositis"},{"@xml:lang":"sl","#text":"Drug therapy"},{"@xml:lang":"sl","#text":"Etiology"},{"@xml:lang":"sl","#text":"Kidney diseases"},{"@xml:lang":"sl","#text":"Therapeutic use"}],"dcterms:temporal":{"@rdf:resource":"1992-2025"},"dc:title":{"@xml:lang":"sl","#text":"Cyclosporin for the treatment of dermatomyositis|"},"dc:description":{"@xml:lang":"sl","#text":"2 patients with extreme severe dermatomyositis, 2 patients who were at risk because of corticosteroid side effects due to underlying diseases-and 1 patient with amyopathic dermatomyosistis who resistant to previous corticosteroid treatment were treated with 5mg/kg/d cyclosporin A (CSP) and prednisone. CSP treatment has been shown to be beneficial in all 5 patients. CSP treatment was discontinued after 3 and 4 months in 2 of the patients with severe disease course because of renal side effects, which were veresible. In no cases were found underlying malignancies. CSP treatment seems to be a valuable second line drug in extreme severe cases of dermatomyositis, in cases who are at risk because of corticosteroid side effects, and in patients who are unresponsive to corticosteroid treatment"},"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:DOC-X1P22C2O","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:DOC-X1P22C2O"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:DOC-X1P22C2O/9661c242-979f-42ac-ae92-329e1192d0ac/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Združenje slovenskih dermatovenerologov"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:DOC-X1P22C2O/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:DOC-X1P22C2O"}}}}